BIOMAKERS Secures $8 Million to Scale AI-Driven Precision Oncology Platform
核心洞察
BIOMAKERS (搜索), a San Francisco-based precision medicine company, closed an additional $8 million funding round to transition from infrastructure building to scaling its AI-native oncology intelligence platform.
The company has built an integrated ecosystem combining molecular diagnostics, real-world clinical data, and a tumor biobank with over 100,000 cases across more than 20 countries.
BIOMAKERS (搜索) is deploying proprietary AI technologies to structure clinical data from hospital electronic medical records, positioning itself as critical infrastructure for global precision oncology research and development.
BIOMAKERS (搜索), a precision medicine and oncology intelligence company headquartered in San Francisco, announced the closing of an additional $8 million funding round, marking a pivotal transition from building global diagnostics infrastructure to scaling an AI-native platform designed to accelerate drug and diagnostic development worldwide.
The financing represents a key inflection point as the company shifts focus toward platform scalability and monetization while continuing to expand its comprehensive molecular testing reach across Latin America. BIOMAKERS (搜索) has positioned itself to enable precision oncology at global scale through improved clinical trial execution and enhanced decision-making capabilities for life sciences partners.
Integrated Oncology Ecosystem
BIOMAKERS (搜索) has constructed an integrated oncology ecosystem that combines large-scale molecular diagnostics, longitudinal real-world clinical data, and a diverse, deeply annotated tumor biobank. Operating across more than 20 countries, the company creates direct links between genomic data, biospecimens, and clinical outcomes, establishing an intelligence layer that life sciences companies can leverage to de-risk research and development, expand trial access, and improve decision-making throughout the drug development lifecycle.
The platform includes a tumor biobank containing more than 100,000 cases and growing, high-throughput genomic testing and molecular profiling capabilities, and a continuously expanding clinical-genomic dataset representing under-sampled patient populations essential for regulatory relevance and therapeutic development. By maintaining direct, longitudinal connections to patients, physicians, and healthcare institutions, BIOMAKERS (搜索) enables partners to move seamlessly from data generation to biological insight and clinical execution.
AI-Driven Platform Evolution
With its core infrastructure now established, BIOMAKERS (搜索) is entering a new phase focused on deploying proprietary AI technologies to structure and harmonize real-world clinical data directly from hospital electronic medical records. This approach unlocks previously inaccessible biological and clinical signals at scale, positioning the company as critical infrastructure for global precision oncology research and development.
"This financing marks a transition from building infrastructure to scaling a global platform," said Nicolás Kirchuk, Co-Founder and Chief Executive Officer of BIOMAKERS (搜索). "We've spent years assembling the data, an integrated diagnostic network, and clinical connectivity required to power precision oncology. Now, with AI at the core of our platform, we're positioned to make that intelligence broadly accessible, accelerating the development of next-generation therapies and emerging diagnostic tools worldwide."
Leadership Expansion and Strategic Vision
To support this next phase of growth, BIOMAKERS (搜索) appointed Ezequiel Renzulli as Chief Operating Officer. Renzulli previously held senior leadership roles at BillionToOne (搜索) and Tempus (搜索), where he helped scale AI-driven diagnostics and data platforms for life science partners.
The company's approach has garnered recognition from investors for its unique combination of scientific rigor and operational execution. "Many companies provide data, but few can link genomic insights directly back to real patient samples at scale," said Ben Freeberg, General Partner at Oncology Ventures (搜索). "BIOMAKERS (搜索) has built an end-to-end system that creates durable value for pharma partners while enabling faster, more effective research and development."
Investment and Market Position
The funding round included participation from Labcorp Venture Fund (搜索), Oncology Ventures (搜索), Endurance28 (搜索), Zentynel (搜索), Sonen Capital (搜索), Sky High Fund (搜索), and other strategic investors with deep expertise across life sciences, healthcare technology, and data-driven platforms.
Consuelo Valverde, Founder and Managing Partner of Endurance28 (搜索), emphasized the company's strategic positioning: "We believed in BIOMAKERS (搜索) early because the team showed a rare combination of long-term vision and execution in a highly complex market. They've demonstrated exceptional discipline in combining science, data, and operations into a scalable platform while remaining focused on long-term value creation."
BIOMAKERS (搜索) operates with clinical laboratories in Mexico, Brazil, and Argentina, serving partners across Latin America and the United States while enabling global access to diverse, high-quality data and biospecimens at scale.